Genscript Biotech Corporation (Genscript Biotech) has disclosed plans to spin off and separately list its indirect non-wholly-owned subsidiary, Probio Technology Limited (ProBio), on the Main Board of The Stock Exchange of Hong Kong. ProBio provides the Group’s Biologics and Advanced Therapy Contract Research, Development and Manufacturing Organization services.

The application submitted under Practice Note 15 (PN15) has been cleared by the Listing Committee, which on 14 August 2026 confirmed that the proposed transaction may proceed.

According to the announcement, Genscript Biotech will retain a controlling interest after completion, ensuring ProBio remains a consolidated subsidiary in the Group’s financial statements.

In line with PN15 requirements, the company intends to grant shareholders an assured entitlement to subscribe for ProBio shares through a preferential application mechanism. Specific terms are still under discussion; however, all qualifying shareholders will receive equal treatment.

The spin-off will constitute a deemed disposal under Rule 14.29 of the Listing Rules, and Genscript Biotech will meet all relevant regulatory obligations.

Management emphasized that the transaction remains subject to final regulatory approval, market conditions and other factors, and may not ultimately proceed. Shareholders and investors are advised to exercise caution when dealing in the company’s securities.

The announcement was authorized by Chairman and Executive Director Robin Meng on 4 September 2026.